Readoutin 76d
Gilead Sciences — Sacituzumab Govitecan-hziy
Phase 3 primary completion: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer.
- Date
- Feb 2027
- Type
- Readout
- Indication
- Triple Negative Breast Cancer